Compare BridgeBio Pharma Inc (BBIO) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares China Large-Cap ETF — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while iShares China Large-Cap ETF trades at $34.03. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | FXI | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $41.75 |
52-Week Low | $44.81 | $31.59 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
FXI trades at $33.44, down slightly (-0.12%) on the day, with technical indicators showing mixed signals between bullish moving averages and neutral oscillators. The ETF benefits from China's aggressive AI and EV investments, including a $295 billion AI infrastructure plan and 30% NEV fleet target by 2030. Recent manufacturing rebounds and strong export data provide fundamental support, though geopolitical tensions with the US pose headwinds.
Outlook remains cautiously optimistic given China's tech investment surge and manufacturing recovery. Key opportunities include exposure to AI hardware exports and domestic EV growth, while risks center on US-China trade restrictions and potential valuation pressures. The ETF offers diversified China large-cap access but requires monitoring of geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
